Urologic Surgery Research & Clinical Trials

Prospective Randomized Study of Exercise in Patients Undergoing Urologic Surgery

Inclusion Criteria:

• Adult patients scheduled for operative procedure with an inpatient postoperative stay

• Willing and able to give blood samples, complete a questionnaire, fill out the step log, and return to clinic for 1st post-operative appointment

Exclusion Criteria:

• None

Treatment:

Patients are given a pedometer and asked to record their daily steps in a log. The purpose of this study is to determine if pedometers can aid in increasing patients' physical activity during the perioperative period.

Principal Investigator:

Kenneth Ogan, MD

Co-Investigators:

Viraj Master, MD, PhD, John Pattaras, MD

Frailty as a Predictor of Outcomes in Surgical Patients

Inclusion Criteria:

• Patients already scheduled for major surgery requiring an overnight hospital stay that are willing to do the study's preoperative assessment tools

• Patients must be able to give informed consent and be 18 years and older

Exclusion Criteria:

• Patients diagnosed with severe dementia, Parkinson's disease, or other functional motor disorders

• Patients diagnosed with a stroke and who have residual motor and/or cognitive deficits

• Patients taking carbidopa/levodopa, donepezil hydrochloride, or antidepressant medications

Principal Investigators:

Kenneth Ogan, MD

Co-Investigators & Collaborators:

John Pattaras, MD, and three surgeons from the Department of Surgery: John Sweeney, MD, David Kooby, MD, Shishir Maithel, MD

A prospective, multicenter, single arm, open-label, early feasibility study to evaluate initial safety and device design concept of “HyperQureTM RDN System”, laparoscopic renal denervation therapy, in patients with resistant hypertension on three (3) or more antihypertensive medications or in patients with documented intolerance to antihypertensive medications. 

Inclusion Criteria:

• Aged ≥ 22 and ≤ 80 years old at time of enrollment (consent) 

• Diagnosed with resistant hypertension 

• Office SBP ≥ 140/90 mmHg at Screening Visit 1 & 2, and meets one of following criteria 

1. Resistant hypertension on at least three (3) antihypertensive medications of different classes including a diuretic for at least four (4) weeks prior to consent
2. Medication-Intolerant Hypertension: documented intolerance to three (3) or more classes of antihypertensive medications regardless of current antihypertensive medication use (including no current use)

• Daytime ABP ≥ 135/85 mmHg after a four (4)-week run-in period at Screening Visit 2. 

Exclusion Criteria:

• Has coverage diameter of renal artery less than 2 mm or greater than 11 mm 

• Unstable angina with stent implantation (percutaneous coronary intervention) within three (3) months of enrollment 

• Myocardial infarction within three (3) months of enrollment. 

• Acute heart failure (NYHA III-IV) within three (3) months of enrollment 

• Cerebrovascular accident or transient ischemic attack within three (3) months of enrollment. 

• Atrial fibrillation patients undergoing treatment and not in sinus rhythm 

• Has one (1) or more confirmed anatomical findings in the kidney or renal artery that are not suitable for renal denervation 

• Has one (1) or more medical history or a history of surgery/procedure that is not suitable for renal denervation therapy 

• Has a history of any intervention for underlying renal artery pathology including stenting or balloon angioplasty 

• Individual has an eGFR of < 40 mL/min/1.73m2, using the four (4) variable MDRD 

• Calculation (in mL/min) per 1.73 m2 = 175 x Serum Cr-1.154 x age-0.203 x 1.212 (if patient is black) x 0.742 (if female) 

• Type I diabetes mellitus or uncontrolled type II diabetes mellitus (defined as a plasma Hb1Ac ≥ 9.0%) 

• Requires chronic oxygen support or mechanical ventilation other than nocturnal 

• Respiratory support for sleep apnea (e.g., CPAP, BiPAP) 

• Has documented primary pulmonary hypertension 

• Has an untreated secondary cause of hypertension (either known or suspected) or is 

• Taking drugs that increase sympathetic tone and could contribute to hypertension 

• Has severe cardiac valve stenosis for which, in the opinion of the Investigator, a significant 

• Reduction of blood pressure is contraindicated.

Principal Investigators:

Dr. Janic Lea and Dr. Mohammad Hajiha